Showing 1–7 of 7 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wamaka Kaminyoge, Reuben Simfukwe, Mwiza Singini, Norman Sitali, Felix P Chilunga
…B) face major treatment challenges. Although newer all-oral regimens have transformed adult TB care, their use in younger populations has largely been extrapolated from adult studies, despite important biologic and clinical differences. Systematic and up-to-date evidence on the e…
Alberto Matteelli, Sofia Lovatti, Benedetta Rossi, Luca Rossi
…th of bedaquiline regimen compared with WHO-recommended TPT regimens. Preventing MDR/rifampicin-resistant TB remains a significant challenge for the global elimination of TB. Although the recent WHO recommendation for 6 months of daily Lf is a promising step, expanding the TPT op…
Kabelo Gabriel Kaapu, Vukosi Treasure Makondo, Emilyn Costa Conceição, Ivy Rukasha
…ng patients with MDR- or XDR-TB treated with BDQ-containing regimens in South Africa.: PubMed, Web of Science, and Embase were searched for studies published between January 2016 and July 2024.: Study quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal…
Lies Dina Liastuti, Kelvin Kohar, Haifa Mayang Lestari, Armalya Pritazahra
…lity. Management requires complex, individualized treatment regimens. Emerging evidence suggests that contemporary antituberculosis agents for drug-resistant disease carry significant cardiotoxicity risk. This study aims to evaluate the cardiovascular toxicity of current therapeu…
Md Mahmudul Islam, Md Zahid Hasan, Md Touki Tahamid Tusar, Md Yeamin Hossain, Md Motaher Hossain, et al.
…factor binding. Clinical studies showed that DLM-containing regimens improve culture conversion and treatment success, especially when combined with oral agents such as bedaquiline and linezolid. Safety data indicate that DLM is generally well tolerated, with QT prolongation bein…
Md Zamiur Rahaman, Tahmina Alam, Syeda Shamsun Nahar, Ridwana Nahrin, Israt Jahan Bushra, et al.
… success rates for drug-sensitive TB reached up to 97%. New regimens incorporating bedaquiline and delamanid for multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB) showed cure rates as high as 94.6%. **CONCLUSION:** Overall, shorter treatment regimens were a…
Hanie Sakhi, Maryam Meskini, Mojgan Sheikhpour
… drug-resistant (XDR) strains. Bedaquiline (BDQ)-containing regimens have become important for the treatment of MDR/XDR-TB, and resistance to BDQ is increasing. Understanding genetic mutations is crucial for early detection of BDQ-resistant strains and thus maintaining the effect…